Alta Wealth Advisors LLC trimmed its holding in Eli Lilly and Company by 17.0% during the third quarter, selling 522 shares to end the period with 2,541 shares under management. At quarter-end, the firm’s Eli Lilly stake carried a reported value of $1.94 million. This reduction follows a broader pattern of portfolio adjustments by hedge funds and institutional investors: Sumitomo Mitsui Financial Group added a new position during Q2 worth approximately $27,000, while Bare Financial Services increased its stake by 263.6%, acquiring 29 additional shares and bringing its total to 40 during the same quarter. Overall, 82.53% of Eli Lilly’s outstanding shares are held by institutional investors and hedge funds, underscoring the company’s significance in institutional portfolios.

In its Q3 earnings release, Eli Lilly reported adjusted earnings per share of $7.02, outperforming consensus estimates by $0.60. Quarterly revenue reached $17.60 billion, up 53.9% year-over-year and surpassing analyst projections by $1.51 billion. The company’s net margin stood at 30.99%, with a return on equity of 109.52%. Management reaffirmed its full-year 2025 EPS guidance of between 23.00 and 23.70, while the analysts’ consensus forecast sits at 23.48. These results reflect robust demand for the company’s flagship products across endocrinology and immunology franchises, and they form the basis for continued investor confidence in the company’s top-line growth trajectory.

Eli Lilly declared a quarterly dividend of $1.73 per share, representing a 15.3% increase from the prior payout of $1.50. The dividend will be payable on March 10, with a record date of February 13. On an annualized basis, the dividend totals $6.92 per share, corresponding to a payout ratio of 29.35%. This marks the company’s third consecutive year of double-digit dividend growth and underscores management’s commitment to returning capital to shareholders alongside ongoing share repurchase programs.

Eli Lilly has launched multiple artificial intelligence platforms to enhance its R&D efficiency and strengthen its competitive position. In September, the company introduced TuneLab, an AI-driven drug discovery platform made freely available to emerging biotech firms in exchange for data contributions. In October, Eli Lilly partnered with Nvidia to build the pharmaceutical industry’s most powerful AI supercomputer. Most recently, the company announced the establishment of an AI drug discovery lab in the San Francisco Bay Area, bringing together in-house researchers and Nvidia engineers. These initiatives aim to shorten development timelines and reduce research costs, potentially accelerating the arrival of next-generation therapies across neuroscience, immunology and oncology.